P97/VCP ATPase inhibitors can rescue p97 mutation-linked motor neuron degeneration

• Published in: Brain communications 2022-07, Vol.4 (4), p.fcac176-fcac176
• Main Authors: Wang, F, Li, S, Wang, T Y, Lopez, G A, Antoshechkin, I, Chou, T F
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2632-1297; 2632-1297
• DOI: 10.1093/braincomms/fcac176

Abstract Mutations in p97/VCP cause two motor neuron diseases: inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia and familial amyotrophic lateral sclerosis. How p97 mutations lead to motor neuron degeneration is, however, unknown. Here we used patient-derived induced pluripotent stem cells to generate p97 mutant motor neurons. We reduced the genetic background variation by comparing mutant motor neurons to its isogenic wild type lines. Proteomic analysis reveals that p97R155H/+ motor neurons upregulate several cell cycle proteins at Day 14, but this effect diminishes by Day 20. Molecular changes linked to delayed cell cycle exit are observed in p97 mutant motor neurons. We also find that two p97 inhibitors, CB-5083 and NMS-873, restore some dysregulated protein levels. In addition, two p97 inhibitors and a food and drug administration-approved cyclin-dependent kinase 4/6 inhibitor, Abemaciclib, can rescue motor neuron death. Overall, we successfully used iPSC-derived motor neurons, identified dysregulated proteome and transcriptome and showed that p97 inhibitors rescue phenotypes in this disease model. Wang et al. investigated differential expression of RNA and protein in induced pluripotent stem cells derived motor neurons by comparing disease-causing mutant cells to its isogenic control. Two p97 inhibitors and a cyclin-dependent kinase 4/6 inhibitor restored some dysregulated protein levels and prevented motor neuron death of a disease-causing p97 mutant. Graphical Abstract Graphical abstract